Injectable Lipid-Based Depot Formulations: Where Do We Stand?

Rahnfeld, Lisa; Luciani, Paola (2020). Injectable Lipid-Based Depot Formulations: Where Do We Stand? Pharmaceutics, 12(6), p. 567. MDPI 10.3390/pharmaceutics12060567

[img]
Preview
Text
pharmaceutics-12-00567.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (5MB) | Preview

The remarkable number of new molecular entities approved per year as parenteral drugs, such as biologics and complex active pharmaceutical ingredients, calls for innovative and tunable drug delivery systems. Besides making these classes of drugs available in the body, injectable depot formulations offer the unique advantage in the parenteral world of reducing the number of required injections, thus increasing effectiveness as well as patient compliance. To date, a plethora of excipients has been proposed to formulate depot systems, and among those, lipids stand out due to their unique biocompatibility properties and safety profile. Looking at the several long-acting drug delivery systems based on lipids designed so far, a legitimate question may arise: How far away are we from an ideal depot formulation? Here, we review sustained release lipid-based platforms developed in the last 5 years, namely oil-based solutions, liposomal systems, in situ forming systems, solid particles, and implants, and we critically discuss the requirements for an ideal depot formulation with respect to the used excipients, biocompatibility, and the challenges presented by the manufacturing process. Finally, we delve into lights and shadows originating from the current setups of in vitro release assays developed with the aim of assessing the translational potential of depot injectables.

Item Type:

Journal Article (Review Article)

Division/Institute:

08 Faculty of Science > Department of Chemistry, Biochemistry and Pharmaceutical Sciences (DCBP)

UniBE Contributor:

Rahnfeld, Lisa, Luciani, Paola

Subjects:

600 Technology > 610 Medicine & health
600 Technology > 610 Medicine & health > 615 Pharmacology & therapeutics, prescription drugs

ISSN:

1999-4923

Publisher:

MDPI

Funders:

[UNSPECIFIED] Phospholipid Research Center

Language:

English

Submitter:

Paola Luciani

Date Deposited:

24 Jun 2020 17:19

Last Modified:

05 Dec 2022 15:39

Publisher DOI:

10.3390/pharmaceutics12060567

BORIS DOI:

10.7892/boris.144836

URI:

https://boris.unibe.ch/id/eprint/144836

Actions (login required)

Edit item Edit item
Provide Feedback